Literature DB >> 21128932

Application and validation of a diagnostic algorithm for the atherogenic apoB dyslipoproteinemias: ApoB dyslipoproteinemias in a Dutch population-based study.

Suzanne Holewijn1, Allan D Sniderman, Martin den Heijer, Dorine W Swinkels, Anton F H Stalenhoef, Jacqueline de Graaf.   

Abstract

BACKGROUND: We applied a diagnostic algorithm using apolipoprotein B (apoB) in combination with triglycerides (TG) and total cholesterol to determine the prevalence of dyslipoproteinemias in the general population. We also characterized the overall cardiovascular (CV) risk profiles, including arterial structure and function as measured with a panel of noninvasive parameters.
DESIGN: Clinical and biochemical characteristics and noninvasive measurements of atherosclerosis (NIMA) were determined in 1517 individuals, aged 50-70 years.
RESULTS: In general, all dyslipoproteinemias were characterized by a worse CV risk profile and deteriorated outcomes of NIMA compared to those with normal apolipoprotein B (< 1·2 g L(-1)) and TG (< 1·5 mM) levels. The prevalence of hyperapoB-hyperTG was 15·1%, and these individuals showed the most abnormal atheroma-related parameters: reduced ankle-brachial-index at rest (-3·5%) and after exercise (-9·8%), increased intima-media thickness (+5·5%) and more carotid plaques (+39·1%). The prevalence of normoapoB-hyperTG because of increased VLDL was 18·1% and 2·3% because of increased chylomicrons and VLDL, and in these groups, the parameters related to stiffness (e.g. pulse-wave-velocity +7·6% and +5·2%, respectively) were most abnormal. Adjustment for apolipoprotein B (apoB) reduced differences in NIMA in the hyperapoB-hyperTG group, whereas adjustment for TG reduced differences in NIMA in the normoapoB-hyperTG group.
CONCLUSIONS: The overall prevalence of dyslipoproteinemias according to the algorithm was approximately 40% in the Dutch population. The different dyslipoproteinemias showed a less favourable CV risk profile and deteriorated NIMA parameters, reflecting increased subclinical atherosclerosis. Furthermore, different effects on different NIMA parameters were observed in the different dyslipoproteinemias.
© 2010 The Authors. European Journal of Clinical Investigation © 2010 Stichting European Society for Clinical Investigation Journal Foundation.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 21128932     DOI: 10.1111/j.1365-2362.2010.02426.x

Source DB:  PubMed          Journal:  Eur J Clin Invest        ISSN: 0014-2972            Impact factor:   4.686


  5 in total

1.  A Modern Approach to Dyslipidemia.

Authors:  Amanda J Berberich; Robert A Hegele
Journal:  Endocr Rev       Date:  2022-07-13       Impact factor: 25.261

2.  Modern prevalence of the Fredrickson-Levy-Lees dyslipidemias: findings from the Very Large Database of Lipids and National Health and Nutrition Examination Survey.

Authors:  Vasanth Sathiyakumar; Vincent A Pallazola; Jihwan Park; Rachit M Vakil; Peter P Toth; Mariana Lazo-Elizondo; Renato Quispe; Eliseo Guallar; Maciej Banach; Roger S Blumenthal; Steven R Jones; Seth S Martin
Journal:  Arch Med Sci       Date:  2019-08-03       Impact factor: 3.318

3.  Modern prevalence of dysbetalipoproteinemia (Fredrickson-Levy-Lees type III hyperlipoproteinemia).

Authors:  Vincent A Pallazola; Vasanth Sathiyakumar; Jihwan Park; Rachit M Vakil; Peter P Toth; Mariana Lazo-Elizondo; Emily Brown; Renato Quispe; Eliseo Guallar; Maciej Banach; Roger S Blumenthal; Steven R Jones; David Marais; Daniel Soffer; Allan D Sniderman; Seth S Martin
Journal:  Arch Med Sci       Date:  2019-08-02       Impact factor: 3.318

4.  The effects of treatment on lipoprotein subfractions evaluated by polyacrylamide gel electrophoresis in patients with autoimmune hypothyroidism and hyperthyroidism.

Authors:  Zuzana Minarikova; Ludovit Gaspar; Peter Kruzliak; Zuzana Celecová; Stanislav Oravec
Journal:  Lipids Health Dis       Date:  2014-10-10       Impact factor: 3.876

5.  Discordance between apolipoprotein B or non-HDL-cholesterol and LDL-cholesterol in middle-aged and elderly Chinese patients predicts arterial stiffness.

Authors:  Geyue Qu; Zhongying Zhang; Hong Zhu
Journal:  Lipids Health Dis       Date:  2021-07-29       Impact factor: 3.876

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.